Milk-derived phosphorylated peptide capable of improving intestinal iron absorption activity and application of milk-derived phosphorylated peptide in preparation of iron supplement
By developing milk source phosphorylated peptides, the shortcomings of existing iron supplements in improving intestinal iron absorption were solved. Using its powerful iron chelation ability, the iron transport volume in the Caco-2 cell model has been significantly improved, and the more Efficient iron bioavailability.
Patent Information
- Application Number
- CN202411126894.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-16
AI Technical Summary
Existing iron supplements have shortcomings in improving intestinal iron absorption, especially because the phosphoric acid and other metal ions in the diet affect iron absorption, making it difficult to effectively solve the problem of iron deficiency.
Develop a milk-derived phosphorylated peptide with a sequence of EESITRINKKIE, with 1 to 3 phosphoserine phosphate at the amino terminal, which can specifically bind to Fe2+, significantly increase the iron transport volume in the Caco-2 small intestinal epithelial cell model, and is used to prepare iron supplementation agent.
This milk source phosphorylated peptide significantly improves the intestinal iron absorption activity, has strong iron chelation ability, can be widely used in medicines, health products or food fields, and provides more effective iron bioavailability.
Smart Images

Figure CN119039415A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of small molecule peptides, and more specifically, to a milk-derived phosphorylated peptide capable of enhancing intestinal iron absorption activity and application thereof in the preparation of an iron supplement. Background Art
[0002] Iron is one of the essential trace elements for the human body, existing in the form of heme iron and non-heme iron. Iron is mainly involved in the production of hemoglobin and oxygen transport. In order for the human body to have enough hemoglobin, it is usually necessary to supplement iron reasonably. Iron deficiency can seriously affect human health and cause iron deficiency anemia and nervous system diseases.
[0003] Many staple foods in the diet (cereals, corn, rice, etc.) usually contain phosphoric acid, phytic acid and oxalic acid, which will complex and precipitate with iron ions in the intestines, affecting the absorption and utilization of iron ions by the intestines, and are the main factors leading to iron deficiency. In addition, the intake of other metal ions also affects the bioavailability of iron in the human body. For example, when a large amount of dietary calcium is consumed, it will significantly reduce the intestinal absorption of iron in a dose-dependent manner.
[0004] To solve the problem of iron deficiency, various iron supplements have appeared on the market, including inorganic iron (ferrous sulfate), organic iron (ferric gluconate), amino acid iron chelates and food-derived iron chelate peptides. The addition of inorganic iron to food will cause changes in its physical, chemical and sensory properties. For example, the addition of ferrous sulfate to infant cereals and tortillas will produce unacceptable color changes and metallic taste. Organic iron supplements are less irritating to the intestines, but due to their low iron content and poor solubility in the gastrointestinal environment, they are not effective in promoting the bioavailability of iron. Amino acid iron chelators such as ferrous glycine can significantly improve the intestinal absorption of iron compared to ferrous sulfate, but due to their high price and the tendency to cause color reactions and lipid oxidation, they have gradually been replaced.
[0005] Iron supplements in which the iron source is added in the form of peptide iron chelates have a good effect on promoting iron bioavailability and can effectively solve the problem of iron deficiency. This is because peptide iron chelates still have advantages such as high solubility, good stability and high safety in the intestine. For example, Miao et al. (see document DOI: 10.1039 / c8fo02414f) isolated iron chelate peptides from bovine casein, but there are still few studies on iron chelate peptides.
[0006] Therefore, more iron chelating peptides need to be developed to meet the current demand for iron supplementation in nutritional supplementation, disease treatment, etc. Summary of the invention
[0007] The primary purpose of the present invention is to overcome the problem that iron chelating peptides are still relatively scarce, and to provide a milk-derived phosphorylated peptide that has the activity of enhancing intestinal iron absorption.2+ It has specific binding, strong iron chelating ability, and can significantly increase the amount of iron transport in the Caco-2 small intestinal epithelial cell model, thus having good activity in enhancing intestinal iron absorption and can be widely used in the fields of medicine, health products or food.
[0008] A further object of the present invention is to provide a use of the milk-derived phosphorylated peptide in the preparation of an iron supplement.
[0009] The above-mentioned object of the present invention is achieved by the following technical solutions:
[0010] A milk-derived phosphorylated peptide having the activity of improving intestinal iron absorption, wherein the milk-derived phosphorylated peptide is a sequence shown in SEQ ID NO: 1, and the glutamic acid at the amino end of the sequence is connected to 1 to 3 phosphoserines.
[0011] The inventors of the present invention extracted a milk-derived phosphorylated peptide with the activity of enhancing intestinal iron absorption from β-casein, the sequence of which is EESITRINKKIE and the glutamic acid at the amino end of the sequence is connected to 1 to 3 phosphoserines. The structural formula of phosphoserine (represented by Sp) is as follows:
[0012] Phosphoserine forms peptides through dehydration condensation reactions between its amino and carboxyl groups and other amino acids.
[0013] The inventors of the present invention have found that the milk-derived phosphorylated peptide of the present invention can bind to Fe 2+ It has specific binding, strong iron chelating ability, and can significantly increase the amount of iron transport in the Caco-2 small intestinal epithelial cell model, thus having good activity in enhancing intestinal iron absorption and can be widely used in the fields of medicine, health products or food.
[0014] Preferably, the glutamic acid at the amino terminus of the sequence is linked to 1 or 3 phosphoserines, that is, the milk-derived phosphorylated peptide is SpEESITRINKKIE or SpSpSpEESITRINKKIE.
[0015] More preferably, the glutamic acid at the amino terminal of the sequence is connected to three phosphoserines. Studies have shown that SpSpSpEESITRINKKIE has stronger iron chelating ability and better activity in improving intestinal iron absorption.
[0016] The milk-derived phosphorylated peptide of the present invention can be obtained by enzymatic hydrolysis, separation and other operations on β-casein, or by solid phase synthesis.
[0017] The present invention also protects the use of the milk-derived phosphorylated peptide in preparing an iron supplement.
[0018] Preferably, the iron supplement is a medicine.
[0019] More preferably, the drug is a drug for preventing and / or treating iron deficiency anemia, or a drug for preventing and / or treating nervous system diseases.
[0020] More preferably, the drug is an oral preparation.
[0021] Preferably, the iron supplement is a health product.
[0022] More preferably, the health care product is a health care product for improving nutritional anemia.
[0023] More preferably, the health product is a nutritional supplement for supplementing minerals.
[0024] Preferably, the iron supplement is a food.
[0025] Compared with the prior art, the present invention has the following beneficial effects:
[0026] The present invention provides a milk-derived phosphorylated peptide having the activity of enhancing intestinal iron absorption. The milk-derived phosphorylated peptide can bind to Fe 2+ It has specific binding, strong iron chelating ability, and can significantly increase the amount of iron transport in the Caco-2 small intestinal epithelial cell model, thus having good activity in enhancing intestinal iron absorption and can be widely used in the fields of medicine, health products or food. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 This is a graph showing the ferrous ion chelation rate of the β-casein hydrolysate and the ultrafiltration fraction in Example 1.
[0028] Figure 2 This is a result diagram of the ferrous ion chelation rate of each separated component after the first separation in Example 1.
[0029] Figure 3 This is a result diagram of the ferrous ion chelation rate of each separated component after the secondary separation in Example 1.
[0030] Figure 4 Milk-derived phosphorylated peptides and Fe 2+ 3D visualization of docking. Figure 4 A in it is SpEESITRINKKIE and Fe 2+ 3D visualization of the docking; Figure 4 B in it is SpSpSpEESITRINKKIE and Fe 2+ 3D visualization of the docking.
[0031] Figure 5 This is a graph showing the iron chelation rate results of SpEESITRINKKIE and SpSpSpEESITRINKKIE of the present invention.
[0032] Figure 6 The graph shows the results of cytotoxicity assay of the Mw<10 kDa component, SpEESITRINKKIE and SpSpSpEESITRINKKIE.
[0033] Figure 7 The graph shows the results of the iron transport activity of the Mw < 10 kDa component, SpEESITRINKKIE, and SpSpSpEESITRINKKIE. DETAILED DESCRIPTION
[0034] In order to more clearly and completely describe the technical solution of the present invention, the present invention is further described in detail through specific embodiments below. It should be understood that the specific embodiments described herein are only used to explain the present invention, and are not used to limit the present invention. Various changes can be made within the scope of the rights of the present invention.
[0035] The determination method of the ferrous ion chelating activity of the samples of Example 1 and Example 3 is as follows:
[0036] The sample was dissolved in 50mM sodium acetate buffer at pH=5 at 1mg / mL. Take 250μL of the above solution and add it to a 96-well plate, preheat it at 37℃ in a constant temperature oscillator, take it out after 10 minutes, add 20μL of 0.25mM FeSO4·7H2O, shake and mix, start timing, and after 50min (37℃), add 15μL of 2.5mM ferroxine solution to terminate the reaction. After 10 minutes, measure the absorbance at 562nm with an enzyme marker. Deionized water was used as the control group, and each sample was tested in triplicate. The formula for calculating the chelation rate of ferrous ions is as follows:
[0037] (1) Ferrous ion chelation rate (%) = (Abs 对照 -Abs 样品 ) / Abs 对照 ×100%, where Abs 对照 is the absorbance value of the control group sample, Abs 样品 is the absorbance value of the sample;
[0038] (2) The ability of 1g sample to chelate ferrous ions (mg / g) = 1.116 × chelation rate (mg / g), where the reaction system contains 0.25mg of sample, 0.279 × 10 -3 mg of ferrous ions, if the chelation rate is a, that is, 0.25 mg of sample can chelate (0.279×10 -3 ×a) mg of ferrous ions, that is, 1 g of sample can combine with (1.116×a) mg of ferrous ions.
[0039] Example 1 Enzymatic hydrolysis, separation and peptide identification of β-casein
[0040] 1.1 Enzymatic hydrolysis of β-casein
[0041] Take a certain amount of β-casein, add distilled water with a pH of 10.0 according to the substrate mass concentration of 10%, and heat it in a 50℃ water bath to dissolve. After the β-casein is completely dissolved, adjust the pH value to 7.30 with 1mol / L NaOH or HCl, add bromelain according to the mass ratio of enzyme to substrate of 0.31:100, and enzymolysis at 55℃ for 4.10h. After the enzymolysis is completed, heat to kill the enzyme (95℃, 10min), cool to room temperature, adjust the solution pH to an isoelectric point of 4.6 with 2mol / L HCl, let it stand for 20min, centrifuge (4000r / min, 10min), collect the supernatant, and freeze-dry to obtain the β-casein enzymatic hydrolysis product.
[0042] 1.2 Separation of β-casein hydrolysis products
[0043] The β-casein enzymatic hydrolysis products were separated by an ultrafiltration membrane with a molecular weight of 10 kDa to obtain two ultrafiltration fractions with Mw < 10 kDa and Mw ≥ 10 kDa, which were freeze-dried separately.
[0044] The ferrous ion chelating activity of the β-casein enzymatic hydrolysate and the two ultrafiltration fractions was determined. Figure 1 As shown (different letters indicate significant differences, p < 0.05). Figure 1 It can be seen that the ferrous ion chelation rate of the component with Mw<10kDa is the highest, reaching 34.15±0.46%.
[0045] 1.3 Separation of Mw<10kDa components
[0046] Primary separation: The components with Mw < 10 kDa obtained by ultrafiltration were filtered through a 0.45 μm filter membrane and separated by preparative liquid chromatography using a reverse C18 glass column (20 μm, 15 mm × 460 mm). The chromatographic conditions were as follows: mobile phase A: deionized water containing 0.1% trifluoroacetic acid (TFA); mobile phase B: methanol containing 0.1% TFA; elution gradient: 0-10 min, 10%-20% mobile phase B; 10-30 min, 20%-35% mobile phase B; 30-80 min, 35%-60% mobile phase B; 80-100 min, 60%-70% mobile phase B; 100-120 min, 95%-95% mobile phase B; injection volume: 4 mL; flow rate: 10.0 mL / min; detection wavelengths were 214 nm and 280 nm, respectively. The eluted peaks were collected and concentrated to obtain 8 separated components, which were named F1, F2, F3, F4, F5, F6, F7, and F8, and freeze-dried.
[0047] The 8 separated components were tested for ferrous ion chelation activity, and the results were as follows Figure 2 As shown (different letters indicate significant differences, p < 0.05). Figure 2 It can be seen that the ferrous ion chelating activity of F4 component is significantly higher than that of other components. 2+ The chelation rate was 39.35±0.29%, Fe 2+ The chelating capacity is 43.92±0.32mg / g.
[0048] Secondary separation: The F4 component was filtered through a 0.45 μm filter membrane and further separated by preparative liquid chromatography using a Shimadzu PRC-ODS (K) steel column (5 μm, 4.6 mm × 200 mm). The chromatographic conditions were as follows: mobile phase A: deionized water containing 0.1% trifluoroacetic acid (TFA); mobile phase B: methanol containing 0.1% TFA; elution gradient: 0-35 min, 10%-40% mobile phase B; 35-55 min, 40%-45% mobile phase B; 55-65 min, 45%-50% mobile phase B; 65-85 min, 95%-95% mobile phase B; injection volume: 600 μL; flow rate: 5.0 mL / min; dual detection wavelengths: 214 nm, 280 nm. The elution peaks were collected and concentrated to obtain a total of 6 components, named M1, M2, M3, M4, M5, and M6, which were freeze-dried separately.
[0049] The ferrous ion chelation activity of the six components was determined. Figure 3 As shown (different letters indicate significant differences, p < 0.05). Figure 3 It can be seen that the M4 component exhibits the strongest ferrous ion chelating activity. 2+ The chelation rate was 90.91±0.1%, Fe 2+ The chelating capacity is 101.45±0.11 mg / g.
[0050] 1.4 HPLC-MS / MS identification of highly active iron-chelating peptides
[0051] Take 1 mg of M4 component in a centrifuge tube, add deionized water to prepare a 1 mg / mL sample solution, desalt the sample solution through a C18 desalting column, freeze-dry the solution, reconstitute with 0.1% formic acid water, centrifuge at 4°C, 2000Xg for 8 minutes, take the supernatant and bottle it for online LC-MS / MS analysis. The highly active iron chelating peptide was identified using an LTQ-Orbitrap Velos Pro ETD mass spectrometer connected to a Thermo Easy-nLC liquid phase. The sample injection volume was 12 μL, the C18 analytical column (50 μm×2 μm×15 cm), the column flow rate was 300 nL / min, the column temperature was 30°C, the ion transfer tube temperature was 300°C, and the S-Lens RF Level was 60%. Mobile phase: Phase A is 0.1% formic acid in water, phase B is 0.1% formic acid in acetonitrile; HPLC elution gradient: 0-70 min, 5%-35% mobile phase B; 70-77 min, 35%-100% mobile phase B; 77-82 min, 100%-100% mobile phase B. The mass spectrometry parameters were set as follows: (1) MS: scan range (m / z): 350-2000; resolution: 60,000; AGC target: 1e6; maximum injection time 100 ms (2) CID-MS / MS (full): iso.width (m / z): 1.0; collision energy: 35; dynamic exclusion time: 10 s.
[0052] The software version used for the database search was Proteome Discoverer TM Software 2.5. When searching the database, the raw file was submitted to the Proteome Discoverer server, the protein database that had been established on Uniprot was selected, and then the database search was performed. The search parameters were set as follows: Protein Database: Bos taurus (Bovine) casein.fasta; Dynamic Modification: Phospho / +79.966Da (S); Enzyme Name: No-Enzyme (no specific); Max. Missed Cleavage Sites: 2; Precursor Mass Tolorance: 10ppm; Fragment Mass Tolorance: 0.6Da.
[0053] A total of 232 peptides from enzymatically hydrolyzed β-casein were identified in the M4 fraction, with molecular weights ranging from 712.38 to 3320.52 Da and peptide chain lengths ranging from 6 to 27 amino acids. Among them, peptides with molecular weights below 3 kDa accounted for 99% of the total peptides, and peptides with lengths less than 20 amino acids accounted for 94.4% of the total peptides.
[0054] Example 2 Molecular docking
[0055] Use Discovery Studio Client 2019 software to create a new ferrous ion model. Use the protein preparation tool to hydrogenate and minimize its energy. Select the calculation docking binding energy in the docking module to predict its binding energy. Based on the size of the docking binding energy, screen out the highly active β-casein iron chelate peptide that is stable with ferrous ions.
[0056] The 232 peptides were ranked according to molecular docking binding energy, and 71 peptides were found to be related to Fe 2+ The binding energy is lower than 0, indicating that it can bind Fe 2+ Free binding occurs. 2+ The two milk-derived phosphorylated peptides SpEESITRINKKIE and SpSpSpEESITRINKKIE were combined stably, both of which had key structures of phosphoserine residues and glutamic acid residues. The identification results of the two milk-derived phosphorylated peptides and their peptide characteristics are shown in Table 1.
[0057] Table 1 Identification results and peptide characteristics of milk-derived phosphorylated peptides
[0058]
[0059] SpEESITRINKKIE and SpSpSpEESITRINKKIE with Fe 2+ Theoretical combination model such as Figure 4 The carbonyl oxygen atom and hydroxyl oxygen atom of the carboxyl group in the third amino acid residue (glutamic acid residue) of the SpEESITRINKKIE sequence interact with Fe through metal receptor interaction and charge-charge interaction, respectively. 2+ The bond lengths of Fe-O bonds in the obtained SpEESITRINKKIE-Fe complex are and The oxygen atom of the first phosphoserine residue in the SpSpSpEESITRINKKIE sequence binds to Fe through charge-charge interactions. 2+ The bond length of the Fe-O bond in the obtained SpSpSpEESITRINKKIE-Fe complex is The Fe-O bond lengths in the SpEESITRINKKIE-Fe complex and the Fe-O bond lengths in the SpSpSpEESITRINKKIE-Fe complex are both longer than those in the monomeric iron(IV) oxide. This indicates that the structures of both the SpEESITRINKKIE-Fe complex and the SpSpSpEESITRINKKIE-Fe complex are relatively stable.
[0060] Example 3 Determination of iron chelating activity and cytotoxicity of milk-derived phosphorylated peptides
[0061] 3.1 Verification of iron chelating activity
[0062] The milk-derived phosphorylated peptides SpEESITRINKKIE and SpSpSpEESITRINKKIE obtained by the above screening were synthesized by Nanjing Jiepeptide Biotechnology Co., Ltd. using solid phase synthesis. The purity of both peptides was greater than 98%, and then the chelating activity of ferrous ions was determined. The results are as follows Figure 5 As shown (** is highly significant, p < 0.01). The iron chelation rates of SpEESITRINKKIE and SpSpSpEESITRINKKIE were 87.18±0.89% and 91.15±0.31%, respectively (both of which are higher than those of some existing iron chelating peptides, for example, the iron chelation rate of AVPYPQR was 59.76% (see document DOI:10.1039 / c8fo02414f) and the iron chelation rate of GPAGPHGPPGKDGR was 58.1% (see document DOI:10.1016 / j.jff.2017.06.013)), which were converted into iron chelation abilities of 97.30±1.00 mg / g and 101.72±0.34 mg / g, respectively. Both of them showed good iron chelation abilities; among them, compared with SpEESITRINKKIE, SpSpSpEESITRINKKIE had stronger iron chelation ability.
[0063] 3.2 MTT assay for cytotoxicity
[0064] Caco-2 cells were purchased from American Type Culture Collection (Rockville, MD, USA). Cells of passage 30-35 were selected for subsequent experiments. The complete cell culture medium contained 79% EMEM basal medium, 20% fetal bovine serum, and 1% antibiotics (penicillin and streptomycin). The culture environment was 37°C, 5% CO2, and 95% relative humidity, and the complete cell culture medium was replaced every 2 days.
[0065] The cells were inoculated into T25 culture flasks. When the cell density reached 70%-80%, 0.25% EDTA-trypsin was added and digested at 37°C for 3 min. The cells were passaged at a ratio of 1:3. Caco-2 cells in the logarithmic growth phase were cultured at 5×10 4 The cells were plated into 96-well plates at a density of 100 μg / well and incubated in complete medium for 24 hours to allow the cells to fully adhere to the wall. After that, the cell culture medium was removed, and 100 μL of different concentrations (100, 250, 500, 1000 μg / mL) of Mw < 10 kDa components, SpEESITRINKKIE and SpSpSpEESITRINKKIE sample solutions (dissolved in cell culture medium) were added to the experimental groups, and 8 wells were added for each concentration. The cell culture medium was used as the blank control group and placed in an incubator for 24 hours. The sample solution was removed, and 100 μL of 0.5 mg / mL MTT solution was added for 4 hours. Finally, the MTT solution was removed, 100 μL of DMSO was added to dissolve the purple crystalline product, and the absorbance was measured at 490 nm using a multifunctional microplate reader. The cell viability calculation formula is as follows: Cell viability (%) = (absorbance value of the experimental group / absorbance value of the blank control group) × 100%.
[0066] Cytotoxicity test results Figure 6 As shown in the figure, the survival rate of Caco-2 cells after 24 hours of treatment was above 90%, indicating that each sample had no toxic effect on cells within this concentration range. Therefore, the subsequent iron transport activity experiment was carried out within this concentration range.
[0067] Example 4 Determination of iron transport activity of milk-derived phosphorylated peptides
[0068] Establishment of Caco-2 monolayer cell model: Caco-2 cells of passage 30-35 were selected to establish the small intestinal epithelial monolayer cell model. Before inoculation, 0.5 mL of complete culture medium was added to the upper chamber of a 12-well polyester Transwell membrane culture plate (PET, Corning, 3460), and 1.5 mL of complete culture medium was added to the lower chamber and placed in an incubator for 1 hour to allow equilibrium to improve the cell attachment efficiency. After 1 hour, the complete culture medium in the upper chamber was removed. When the cells grew to 80% of the T25 culture flask, 2×10 5 The cells were inoculated into the upper chamber of a 12-well polyester Transwell membrane culture plate at a density of 100 / mL (0.5 mL of cell suspension was added to the upper chamber). After 21 days of culture, the medium was changed every other day until the cells formed a complete membrane (in the third week, the fetal bovine concentration in the complete culture medium was increased to 25%). The integrity of the cell monolayer membrane was evaluated by measuring the transmembrane electrical resistance (TEER). When the transmembrane resistance was 500-1000Ω / cm 2 The Caco-2 cell monolayer model was successfully established and can be used for transport experiments.
[0069] Before the transport experiment, prepare a new 12-well culture plate and add 1.5 mL of complete culture medium. Transfer the Caco-2 monolayer membrane cultured for 21 days to the new 12-well plate. Mix the prepared FeCl2.4H2O solution and the premixed solution of the Mw < 10 kDa component and FeCl2.4H2O (Fe 2+ The concentration of the component with Mw < 10 kDa was 80 μg / mL, the concentration of the component with Mw < 10 kDa was 568 μg / mL), and the premixed solution of SpEESITRINKKIE and FeCl2.4H2O (Fe 2+ The concentration of SpEESITRINKKIE was 80 μg / mL, the concentration of SpEESITRINKKIE was 568 μg / mL) and the premixed solution of SpSpSp EESITRINKKIE and FeCl2.4H2O (Fe 2+ The concentration of SpSpSpEESI was 80μg / mL and the concentration of TRINKKIE was 568μg / mL) in a 37°C incubator and incubated for 1h. The sample solution (0.5mL) was added to the upper chamber of the Transwell nested plate, and the control group was added with FeCl2.4H2O solution. After the start of transport, 1mL of culture medium was taken from the lower chamber of the Transwell nested plate at 30, 60, 120, and 180min, and 1mL of culture medium was quickly added to maintain the volume of the transport system unchanged. The iron concentration of the culture medium in the lower chamber at each time point was determined by flame atomic absorption spectrometry. The formula for calculating the amount of iron transport at each time point is as follows:
[0070]
[0071] In the formula, T n is the total iron transport amount at each time point (μg); 1.5 is the volume of the lower complete culture medium (mL); C n is the iron concentration in the samples obtained at different time points (μg / mL); 2.64 is the iron concentration in the complete culture medium itself (μg / mL); 1 is the volume of the sample obtained from the lower layer (mL); n is an independent quantity, which can be 1, 2, 3, 4, representing 4 different time points, namely 30min, 60min, 120min, and 180min.
[0072] Iron transport test results Figure 7As shown (different letters indicate significant differences, p < 0.05), at 30 min, the iron transport capacity of the Mw < 10 kDa component, SpEESITRINKKIE and SpSpSpEESITRINKKIE increased by 74 ± 3%, 79 ± 1% and 129 ± 2% respectively compared with the control group with FeCl2.4H2O, indicating that the milk-derived phosphorylated peptide of the present invention promotes intestinal iron absorption and significantly increases the bioavailability of iron in Caco-2 cells. As time goes by, the iron transport capacity of SpSpSpEESITRINKKIE is always higher than that of SpEESITRINKKIE, and has a stronger effect of promoting iron absorption.
[0073] Through Examples 1 to 4, it is shown that the milk-derived phosphorylated peptide of the present invention can bind to Fe 2+ It has specific binding, strong iron chelating ability, and can significantly increase the amount of iron transport in the Caco-2 small intestinal epithelial cell model, thus having good activity in enhancing intestinal iron absorption.
[0074] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A milk-derived phosphorylated peptide having the activity of enhancing intestinal iron absorption, characterized in that: The milk-derived phosphorylated peptide is a sequence shown in SEQ ID NO: 1, and the glutamic acid at the amino terminal of the sequence is connected to 1 to 3 phosphoserines.
2. The milk-derived phosphorylated peptide according to claim 1, characterized in that: The amino-terminal glutamic acid of the sequence is linked to 1 or 3 phosphoserines.
3. Use of the milk-derived phosphorylated peptide according to claim 1 or 2 in the preparation of an iron supplement.
4. The use according to claim 3, characterized in that: The iron supplement is a medicine.
5. The use according to claim 4, characterized in that: The medicine is a medicine for preventing and / or treating iron deficiency anemia, or a medicine for preventing and / or treating nervous system diseases.
6. The use according to claim 4, characterized in that: The medicine is an oral preparation.
7. The use according to claim 3, characterized in that: The iron supplement is a health product.
8. The use according to claim 7, characterized in that The health care product is a health care product for improving nutritional anemia.
9. The use according to claim 7, characterized in that: The health care product is a nutritional supplement for supplementing minerals.
10. The use according to claim 3, characterized in that: The iron supplement is a food.
Citation Information
Patent Citations
Multi-phosphopeptide-enriched casein hydrolyzate and preparation method thereof
CN101948524A
Bioactive polypeptide FPKYPVEPF, and preparation and application thereof
CN108017701A
Method for producing casein and uses thereof
US20240251812A1
Method for detecting epitopes in allergen or candidates for the epitopes, and use of the epitopes or the candidates
WO2010052939A1
Cited By
Dendrobium polysaccharide iron chelate and preparation method thereof
CN120078804A
